|
1
|
Sculier JP, Berghmans T and Meert AP:
Small cell lung cancer: What are the treatment results in routine
management? Lung Cancer. 84:101–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tran YK, Bogler O, Gorse KM, Wieland I,
Green MR and Newsham IF: A novel member of the NF2/ERM/4.1
superfamily with growth suppressing properties in lung cancer.
Cancer Res. 59:35–43. 1999.PubMed/NCBI
|
|
3
|
Takakuwa Y: Protein 4.1, a multifunctional
protein of the erythrocyte membrane skeleton: Structure and
functions in erythrocytes and nonerythroid cells. Int J Hematol.
72:298–309. 2000.
|
|
4
|
Steenbergen RD, Kramer D, Braakhuis BJ,
Stern PL, Verheijen RH, Meijer CJ and Snijders PJ: TSLC1 gene
silencing in cervical cancer cell lines and cervical neoplasia. J
Natl Cancer Inst. 96:294–305. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu B, Di W, Wang H, Ma H, Li J and Zhang
Q: Tumor suppressor TSLC1 is implicated in cell proliferation,
invasion and apoptosis in laryngeal squamous cell carcinoma by
regulating Akt signaling pathway. Tumour Biol. 33:2007–2017. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heller G, Geradts J, Ziegler B, Newsham I,
Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer
W, Depisch D, et al: Downregulation of TSLC1 and DAL-1 expression
occurs frequently in breast cancer. Breast Cancer Res Treat.
103:283–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito T, Shimada Y, Hashimoto Y, Kaganoi J,
Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1
in progression of esophageal squamous cell carcinoma. Cancer Res.
63:6320–6326. 2003.PubMed/NCBI
|
|
8
|
Mao X, Seidlitz E, Truant R, Hitt M and
Ghosh HP: Re-expression of TSLC1 in a non-small-cell lung cancer
cell line induces apoptosis and inhibits tumor growth. Oncogene.
23:5632–5642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kikuchi S, Yamada D, Fukami T, Masuda M,
Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y,
Onizuka M and Murakami Y: Promoter methylation of DAL-1/4.1B
predicts poor prognosis in non-small cell lung cancer. Clin Cancer
Res. 11:2954–2961. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goto A, Niki T, Chi-Pin L, Matsubara D,
Murakami Y, Funata N and Fukayama M: Loss of TSLC1 expression in
lung adenocarcinoma: Relationships with histological subtypes, sex
and prognostic significance. Cancer Sci. 96:480–486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gutmann DH, Hirbe AC, Huang ZY and Haipek
CA: The protein 4.1 tumor suppressor, DAL-1, impairs cell motility,
but regulates proliferation in a cell-type-specific fashion.
Neurobiol Dis. 8:266–278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robb VA, Gerber MA, Hart-Mahon EK and
Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B
is necessary and sufficient for meningioma growth suppression.
Oncogene. 24:1946–1957. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Franco-Chuaire ML, Magda Carolina SC and
Chuaire-Noack L: Epithelial-mesenchymal transition (EMT):
Principles and clinical impact in cancer therapy. Invest Clin.
54:186–205. 2013.PubMed/NCBI
|
|
14
|
Nieto MA: Epithelial-Mesenchymal
Transitions in development and disease: Old views and new
perspectives. Int J Dev Biol. 53:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elliott RL and Blobe GC: Role of
transforming growth factor Beta in human cancer. J Clin Oncol.
23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goel A, Chhabra R, Ahmad S, Prasad AK,
Parmar VS, Ghosh B and Saini N: DAMTC regulates cytoskeletal
reorganization and cell motility in human lung adenocarcinoma cell
line: An integrated proteomics and transcriptomics approach. Cell
Death Dis. 3:e4022012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tran Y, Benbatoul K, Gorse K, Rempel S,
Futreal A, Green M and Newsham I: Novel regions of allelic deletion
on chromosome 18p in tumors of the lung, brain and breast.
Oncogene. 17:3499–505. 1998. View Article : Google Scholar
|
|
19
|
Yageta M, Kuramochi M, Masuda M, Fukami T,
Fukuhara H, Maruyama T, Shibuya M and Murakami Y: Direct
association of TSLC1 and DAL-1, two distinct tumor suppressor
proteins in lung cancer. Cancer Res. 62:5129–5133. 2002.PubMed/NCBI
|
|
20
|
Zhang Y, Xu R, Li G, Xie X, Long J and
Wang H: Loss of expression of the differentially expressed in
adenocarcinoma of the lung (DAL-1) protein is associated with
metastasis of non-small cell lung carcinoma cells. Tumour Biol.
33:1915–1925. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bernkopf DB and Williams ED: Potential
role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of
advanced prostate cancer. Expert Opin Ther Targets. 12:845–853.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cavanna T, Pokorna E, Vesely P, Gray C and
Zicha D: Evidence for protein 4.1B acting as a metastasis
suppressor. J Cell Sci. 120:606–616. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohno N, Terada N, Murata S, Yamakawa H,
Newsham IF, Katoh R, Ohara O and Ohno S: Immunolocalization of
protein 4.1B/DAL-1 during neoplastic transformation of mouse and
human intestinal epithelium. Histochem Cell Biol. 122:579–586.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Christofori G and Semb H: The role of the
cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Q, Mao H, Nie J, Chen W, Yang Q, Dong
X and Yu X: Transforming growth factor {beta}1 induces
epithelial-mesenchymal transition by activating the JNK-Smad3
pathway in rat peritoneal mesothelial cells. Perit Dial Int.
28(Suppl 3): S88–S95. 2008.PubMed/NCBI
|
|
26
|
Xu XL, Ling ZQ, Chen SZ, Li B, Ji WH and
Mao WM: The impact of E-cadherin expression on the prognosis of
esophageal cancer: A meta-analysis. Dis Esophagus. 27:79–86. 2014.
View Article : Google Scholar
|
|
27
|
Nakaya Y and Sheng G: EMT in developmental
morphogenesis. Cancer Lett. 341:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito A: EMT and EndMT: Regulated in
similar ways? J Biochem. 153:493–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Willis BC and Borok Z: TGF-beta-induced
EMT: Mechanisms and implications for fibrotic lung disease. Am J
Physiol Lung Cell Mol Physiol. 293:L525–L534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duangkumpha K, Techasen A, Loilome W,
Namwat N, Thanan R, Khuntikeo N and Yongvanit P: BMP-7 blocks the
effects of TGF-beta-induced EMT in cholangiocarcinoma. Tumour Biol.
35:9667–9676. 2014. View Article : Google Scholar : PubMed/NCBI
|
